Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients

Genome editing with engineered nucleases has recently emerged as an approach to correct genetic mutations by enhancing homologous recombination with a DNA repair template. However, many genetic diseases, such as Duchenne muscular dystrophy (DMD), can be treated simply by correcting a disrupted reading frame. We show that genome editing with transcription activator-like effector nucleases (TALENs), without a repair template, can efficiently correct the reading frame and restore the expression of a functional dystrophin protein that is mutated in DMD. TALENs were engineered to mediate highly efficient gene editing at exon 51 of the dystrophin gene. This led to restoration of dystrophin protein expression in cells from Duchenne patients, including skeletal myoblasts and dermal fibroblasts that were reprogrammed to the myogenic lineage by MyoD. Finally, exome sequencing of cells with targeted modifications of the dystrophin locus showed no TALEN-mediated off-target changes to the protein-coding regions of the genome, as predicted by in silico target site analysis. This strategy integrates the rapid and robust assembly of active TALENs with an efficient gene-editing method for the correction of genetic diseases caused by mutations in non-essential coding regions that cause frameshifts or premature stop codons.

[1]  Matthew J. Moscou,et al.  A Simple Cipher Governs DNA Recognition by TAL Effectors , 2009, Science.

[2]  A. Wagers,et al.  Highly Efficient, Functional Engraftment of Skeletal Muscle Stem Cells in Dystrophic Muscles , 2008, Cell.

[3]  Thuy D Vo,et al.  Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures , 2011, Nature Methods.

[4]  J. Corbeil,et al.  Endonucleases: tools to correct the dystrophin gene , 2011, The journal of gene medicine.

[5]  Claudio Mussolino,et al.  A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity , 2011, Nucleic acids research.

[6]  J. Keith Joung,et al.  TALENs: a widely applicable technology for targeted genome editing , 2012, Nature Reviews Molecular Cell Biology.

[7]  A. Bradley,et al.  Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells , 2011, Nature.

[8]  Tobias Schmidt,et al.  A ligation-independent cloning technique for high-throughput assembly of transcription activator–like effector genes , 2012, Nature Biotechnology.

[9]  Jens Boch,et al.  Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors , 2009, Science.

[10]  M. Oshimura,et al.  Stem Cell–Mediated Transfer of a Human Artificial Chromosome Ameliorates Muscular Dystrophy , 2011, Science Translational Medicine.

[11]  Thomas Gaj,et al.  Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. , 2010, Journal of molecular biology.

[12]  C. Gersbach,et al.  Highly active zinc-finger nucleases by extended modular assembly , 2013, Genome research.

[13]  J. Orange,et al.  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases , 2008, Nature Biotechnology.

[14]  Huimin Zhao,et al.  Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. , 2012, Molecular bioSystems.

[15]  F. Muntoni,et al.  Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders , 2011, Skeletal Muscle.

[16]  M. Oshimura,et al.  Transplantation of Genetically Corrected Human iPSC-Derived Progenitors in Mice with Limb-Girdle Muscular Dystrophy , 2012, Science Translational Medicine.

[17]  Eunji Kim,et al.  Targeted chromosomal deletions in human cells using zinc finger nucleases. , 2010, Genome research.

[18]  M. Hoshino,et al.  Mari Dezawa Degeneration Bone Marrow Stromal Cells Generate Muscle Cells and Repair Muscle , 2013 .

[19]  J. Rousseau,et al.  Meganucleases can restore the reading frame of a mutated dystrophin , 2010, Gene Therapy.

[20]  M. Rudnicki,et al.  Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Hojun Li,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[22]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[23]  Kevin Kim,et al.  A TALEN genome-editing system for generating human stem cell-based disease models. , 2013, Cell stem cell.

[24]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[25]  Yoshio Kato,et al.  targeted gene knockout by direct delivery of zinc-finger nuclease proteins , 2012 .

[26]  K. Davies,et al.  Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  M. Kyba,et al.  Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. , 2012, Cell stem cell.

[28]  J. Shay,et al.  Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin‐dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies , 2007, Aging cell.

[29]  T. Cathomen,et al.  Quantification of zinc finger nuclease-associated toxicity. , 2010, Methods in molecular biology.

[30]  G. Butler-Browne,et al.  In vivo myogenic potential of human CD133+ muscle-derived stem cells: a quantitative study. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  Meenal Patel,et al.  PTC124 targets genetic disorders caused by nonsense mutations , 2007, Nature.

[32]  Livija Medne,et al.  Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort , 2009, Human mutation.

[33]  F. Muntoni,et al.  The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  C. Gersbach,et al.  Advances in targeted genome editing. , 2012, Current opinion in chemical biology.

[35]  Jeffry D Sander,et al.  FLAsH assembly of TALeNs for high-throughput genome editing , 2022 .

[36]  Elo Leung,et al.  A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.

[37]  Charles A. Gersbach,et al.  Gene targeting to the ROSA26 locus directed by engineered zinc finger nucleases , 2011, Nucleic acids research.

[38]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[39]  J. Grieger,et al.  Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  S. Tapscott,et al.  Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. , 2008, Human molecular genetics.

[41]  J. Mendell,et al.  Dystrophin immunity in Duchenne's muscular dystrophy. , 2010, The New England journal of medicine.

[42]  Volker Brendel,et al.  TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction , 2012, Nucleic Acids Res..

[43]  P. Mali,et al.  Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. , 2011, Blood.

[44]  Erin L. Doyle,et al.  Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting , 2011, Nucleic acids research.

[45]  Toni Cathomen,et al.  Autonomous zinc-finger nuclease pairs for targeted chromosomal deletion , 2010, Nucleic acids research.

[46]  Morgan L. Maeder,et al.  In Situ Genetic Correction of the Sickle Cell Anemia Mutation in Human Induced Pluripotent Stem Cells Using Engineered Zinc Finger Nucleases , 2011, Stem cells.

[47]  Jiyeon Kweon,et al.  TALENs and ZFNs are associated with different mutation signatures , 2013, Nature Methods.

[48]  Erin L. Doyle,et al.  Targeting DNA Double-Strand Breaks with TAL Effector Nucleases , 2010, Genetics.

[49]  M. G. Cusella De Angelis,et al.  High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. , 1998, The Journal of clinical investigation.